Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience

References

• Cormier JN, Pollock RE. Soft tissue sarcoma. CA Cancer J Clin 2004;54:94–109
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb sparring surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305–15
   PubMed Web of Science ®Google Scholar
• Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;3:269–75
   Google Scholar
• Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616–32
   PubMed Web of Science ®Google Scholar
• Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, et al. Selective heat sensibility of cancer cells: Biochemical and clinical studies. Cancer 1967;20:1351–81
   PubMed Web of Science ®Google Scholar
• Stehlin JS Jr. Hypertermic perfusion with chemotherapy for cancers of extremities. Surg Gynecol Obstet 1969;129:305–8
   PubMedGoogle Scholar
• Taeger G, Grabellus F, Podleska LE, Müller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia 2008;24:193–203
   PubMed Web of Science ®Google Scholar
• Bhangu A, Broom L, Nepogodiev D, Gourevitch D, Desai A. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: A systematic review. Eur J Surg Oncol 2013;39:311–19
   PubMed Web of Science ®Google Scholar
• Seinen JM, Hoekstra HJ. Isolated limb perfusion of soft tissue sarcomas: A comprehensive review of literature. Cancer Treat Rev 2013;39:569–77
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Liénard D, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756–64
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor α for advanced melanoma and soft tissue sarcoma. Ann Surg Oncol 2007;14:230–8
   PubMed Web of Science ®Google Scholar
• Deroose JP, Grünhagen DJ, de Wilt JH, Eggermont AM, Verhoef C. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas. Eur J Cancer 2015;51:367–73
   PubMed Web of Science ®Google Scholar
• Rossi CR, Vecchiato A, Foletto M, Nitti D, Ninfo V, Fornasiero A, et al. Phase II study on neoadjuvant hyperthermic antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994;73:2140–6
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Cavaliere F, Anzà M, Garinei R, Botti C, Perri P, et al. Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma. J Chemother 2004;16:66–9
   PubMed Web of Science ®Google Scholar
• Rossi C, Foletto M, Vecchiato A, Menin N, Pizzirani E, Di Filippo F, et al. TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcoma. Oncol Rep 1996;3:1059–61
   PubMed Web of Science ®Google Scholar
• Rossi CR, Mocellin S, Pilati P, Foletto M, Nitti D, Lise M. TNF alpha-based isolated perfusion for limb-threatening soft tissue sarcomas: State of the art and future trend. J Immunother 2003;26:291–300
   PubMed Web of Science ®Google Scholar
• Hoven-Gondrie ML, Bastiaannet E, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome. J Surg Oncol 2011;103:648–55
   PubMed Web of Science ®Google Scholar
• Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429–37
   PubMed Web of Science ®Google Scholar
• Rossi CR, Foletto M, DI Filippo F, Vaglini M, Anza' M, Azzarelli A, et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 1999;86:1742–9
   PubMed Web of Science ®Google Scholar
• Casara D, Rubello D, Pilati P, Scalerta R, Foletto M, Rossi CR. Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA. Nucl Med Commun 2004;25:61–6
   PubMed Web of Science ®Google Scholar
• Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reaction. Eur J Cancer Clin Oncol 1982;18:905–10
   PubMedGoogle Scholar
• Di Filippo F, Giacomini P, Rossi CR, Santinami M, Garinei R, Anzà M, et al. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: The experience of the Italian Society of Integrated Locoregional Treatment in Oncology. In Vivo 2009;23:363–7
   PubMed Web of Science ®Google Scholar
• Deroose JP, van Geel AN, Burger JW, Eggermont AM, Verhoef A. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol 2012;105:563–9
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 2006;106:156–62
   PubMed Web of Science ®Google Scholar
• Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, et al. Advanced extremity soft tissue sarcoma: Prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol 2007;14:553–9
   PubMed Web of Science ®Google Scholar
• Olofsson R, Bergh P, Berlin O, Engström K, Gunterberg B, Hansson M, et al. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2012;19:1800–7
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, et al. Limb salvage by neoadjuvant isolated perfusion with TNF alpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000;26:669–78
   PubMed Web of Science ®Google Scholar
• Olieman AF, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Hyperthermic isolated limb perfusion with tumour necrosis factor-αlpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile? Arch Orthop Trauma Surg 1998;118:70–4
   PubMed Web of Science ®Google Scholar
• van Ginkel RJ, Thijssens KMJ, Pras E, van der Graaf WT, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: Three time periods at risk for amputation. Ann Surg Oncol 2007;14:1499–506
   PubMed Web of Science ®Google Scholar
• Moller GM, Lewis JM, Dessureault S, Zager JS. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia 2008;24:275–89
   PubMed Web of Science ®Google Scholar
• Levy A, Le Péchoux C, Terrier P, Bouaita R, Domont J, Mir O, et al. Epithelioid sarcoma: Need for a multimodal approach to maximize the chances of curative conservative treatment. Ann Surg Oncol 2014;21:269–76
   PubMed Web of Science ®Google Scholar
• Grabellus F, Kraft C, Sheu-Grabellus SY, Bauer S, Podleska LE, Lauenstein TC, et al. Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-α and melphalan. J Surg Oncol 2011;103:371–9
   PubMed Web of Science ®Google Scholar
• Padussis JC, Steerman SN, Tyler DS, Mosca PJ. Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI. Int J Hyperthermia 2008;24:239–49
   PubMed Web of Science ®Google Scholar
• Beasley GM, Ross MI, Tyler DS. Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia 2008;24:301–9
   PubMed Web of Science ®Google Scholar
• Vohra NA, Turaga KK, Gonzalez RJ, Conley A, Reed D, Bui MM. The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia 2013;29:1–7
   PubMed Web of Science ®Google Scholar
• Campana LG, Bianchi G, Mocellin S, Valpione S, Campanacci L, Brunello A, Donati D, Sieni E, Rossi CR. Electrochemotherapy treatment of locally advanced and metastatic soft tissue sarcomas: Results of a non-comparative phase II study. World J Surg 2014;38:813–22
   PubMed Web of Science ®Google Scholar
• Olieman AF, Pras E, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 1998;40:807–14
   PubMed Web of Science ®Google Scholar
• Thijssens KM, van Ginkel RJ, Pras E, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: The value of adjuvant radiotherapy. Ann Surg Oncol 2006;13:518–24
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Keus RB, Nieweg OE, Kroon BB. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha ± interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol. 1997;65:88–94
   PubMed Web of Science ®Google Scholar
• Hoven-Gondrie ML, Thijssens KM, Van den Dungen JJ, Loonstra J, van Ginkel RJ, Hoekstra HJ. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol 2007;14:2105–12
   PubMed Web of Science ®Google Scholar
• Hoven-Gondrie ML, Thijssens KM, Geertzen JH, Pras E, van Ginkel RJ, Hoekstra HJ. Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: Long-term effects on normal tissue according to the LENT-SOMA scoring system. Ann Surg Oncol 2008;15:1502–10
   PubMed Web of Science ®Google Scholar
• Deroose JP, Burger JW, van Geel AN, den Bakker MA, de Jong JS, Eggermont AM, et al. Radiotherapy for soft tissue sarcoma after isolated limb perfusion and surgical resection: Essential for local control in all patients? Ann Surg Oncol 2011;18:321–7
   PubMed Web of Science ®Google Scholar